Key Points Highlighted
Issues related to all aspects of pharma business, both Russian and CIS were discussed at the VIII Conference “What is Going On in the Pharma Market?” held in Moscow on October 3-4. Lively round-table discussions concerned customs legislation, antimonopoly regulation and approaches to solving problems from both from regulatory and market perspectives.
Issues of pricing and compulsory licensing were at a special focus at the conference.
Elena Maslovskaya, Deputy General Manager of ARPM remarked, that the problem of washing out of lower price segment drugs in pharmacies has not yet been resolved. Explaining the situation she remarked, that gaps in the system of pricing often make manufacturers face a dilemma: to sell drugs below cost or suspend production. Talking about pricing, Lilia Titova, Executive Director of SPFO remarked that lack of uniformity in the process of public purchase and pricing lead to situations, when prices for the same drug in different regions vary by 2-2.5-fold. She added, that monitoring of drug circulation with labeling may help solve the problem. A pilot project on introduction of the new method, as reported earlier, on October 3, is to be launched in 2017.
Timofey Nizhegorodtsev, head of social sphere and trade administration, Russian FAS, called applicants to abandon the imperfect tariff-based pricing and switch to economic analysis-based method. His arguments were based on results of inspections of Russian FAS, which revealed 48 drugs with approved prices higher, than prices for the same drugs in the reference countries.
Alexander Bykov, Pharmacoeconomics Director at SC R-Pharm highlighted the issue of so-called double circulation of expensive drugs. He described cases, where a drug, purchased according to 44-FZ in one region emerged in another region at a lower price. Coming back to the problem of compulsory licensing, quite topical today, Timofey Nizhegorodtsev stressed that the proposal* is based on international practice: introduction of procedure of compulsory licensing is only possible in case of meeting a number of crossing requirements. Authors of the proposal do not attempt to devaluate the intellectual rights of manufacturers, but to create conditions to protect national security.